JP2007505830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505830A5 JP2007505830A5 JP2006525902A JP2006525902A JP2007505830A5 JP 2007505830 A5 JP2007505830 A5 JP 2007505830A5 JP 2006525902 A JP2006525902 A JP 2006525902A JP 2006525902 A JP2006525902 A JP 2006525902A JP 2007505830 A5 JP2007505830 A5 JP 2007505830A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- particles
- composition
- hydrophobic amino
- mucus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000010419 fine particle Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 6
- 230000002209 hydrophobic Effects 0.000 claims 6
- 210000003097 Mucus Anatomy 0.000 claims 5
- 238000010902 jet-milling Methods 0.000 claims 5
- 208000009856 Lung Disease Diseases 0.000 claims 4
- 229920001499 Heparinoid Polymers 0.000 claims 3
- 239000002554 heparinoid Substances 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L Dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 2
- 229960002897 Heparin Drugs 0.000 claims 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims 2
- 201000003883 cystic fibrosis Diseases 0.000 claims 2
- 229940051593 dermatan sulfate Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 1
- 208000007451 Chronic Bronchitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 230000037250 Clearance Effects 0.000 claims 1
- 229960004776 Danaparoid sodium Drugs 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000003182 bronchodilatating Effects 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 230000035512 clearance Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 description 7
- 230000000996 additive Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 230000000181 anti-adherence Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003831 antifriction material Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
Description
投与効率は乾燥粉末配合物の微粒子の割合(FPF)に非常に依存し、さまざまな賦形剤を加えて、非常に充分なFPFが得られることを確実にする必要がある。
微粒子の割合(FPF)はEDで割ったFPDとして通常定義し、パーセンテージとして表す。本明細書では、EDのFPFはFPF(ED)と呼び、FPF(ED)=(FPD/ED)×100%として計算する。
微粒子の割合(FPF)はMDで割ったFPDとして定義し、パーセンテージとして表すこともできる。本明細書では、MDのFPFはFPF(MD)と呼び、FPF(MD)=(FPD/MD)×100%として計算する。
好ましくは、添加剤物質は抗接着性物質であり、それは粒子間の凝集性を低下させる傾向があり、微粒子が吸入デバイスの内側表面に付着した状態になるのも妨げる。添加剤物質は減摩剤または流動促進剤であり、吸入器中での医薬組成物のより良い流れを与えることが有利である。このように使用される添加剤物質は、通常は必ずしも抗接着剤または減摩剤と呼ぶことはできないが、それらは粒子間の凝集性を低下させる効果、または粉末の流れを改善する効果を有する。添加剤物質は力制御物質(FCA)と呼ばれることが多く、これらは通常はより良い用量再現性および充分な細粒の割合をもたらす。
一般に、乾燥粉末配合物に含まれる添加剤物質の最適量は、添加剤物質および活性剤の化学組成および他の性質、ならびに存在する場合は担体粒子などの他の粒子の性質に依存するであろう。一般に、添加剤物質の有効性は、組成物の細粒の割合に関して測定する。
粉末の処理を試験するために、Monohalerおよび20mgの粉末を充填したカプセルを使用して作業を行い、前に説明した方法で迅速なTSIに移した。この試験は60lpmのTSI流速、および約5μmのカットオフを使用した。
さらに、5μm未満の大きさを有する粒子の質量の割合を粒径データから得て、FPFとして表す。
Claims (30)
1つまたは複数のグリコサミノグリカンおよび疎水性アミノ酸を含む、粘液の浄化を促進するための組成物であって、肺吸入用の乾燥粉末であり、2％ w/w以上の疎水性アミノ酸を含む、組成物。
炎症を低下させることができる、請求項1に記載の組成物。
1つまたは複数の更なる粘液活性剤を含む、請求項1または2に記載の組成物。
1つまたは複数の粘液活性剤が粘液内の架橋を減少させ、粘液を希釈する、請求項1から3のいずれか一項に記載の組成物。
グリコサミノグリカンがヘパリンおよび/またはヘパリノイドである、請求項1に記載の組成物。
ヘパリノイドがダナパロイドナトリウム、またはデルマタン硫酸である、請求項5に記載の組成物。
ヘパリノイドがヘパリン、デルマタン硫酸およびコンドロイチン硫酸を含む、請求項5に記載の組成物。
硫酸化グリコサミノグリカン、ポリ硫酸グリコサミノグリカン化合物、または硫酸化ムコ多糖を含む、請求項1から7のいずれか一項に記載の組成物。
50%と99%の間の微粒子の割合を有し、前記微粒子の割合が、5μm未満の空気力学的粒径を有する粒子の質量割合である、請求項1に記載の組成物。
疎水性アミノ酸が50%w/wまでの量で含まれる、請求項1に記載の組成物。
疎水性アミノ酸がロイシンである、請求項1から10のいずれかに記載の組成物。
10μm未満の空気力学的質量中央径を有するグリコサミノグリカンの粒子を含む、請求項1から11のいずれかに記載の組成物。
粒子が2〜5μmの空気力学的質量中央径を有する、請求項12に記載の組成物。
20μm以上の粒径を有する担体粒子をさらに含む、請求項1から13のいずれか一項に記載の組成物。
治療において使用するための、請求項1から14のいずれか一項に記載の医薬組成物。
肺疾患を治療するための、請求項15に記載の医薬組成物。
肺疾患が粘液の分泌過多または粘液の異常な粘弾性を伴う、請求項16に記載の医薬組成物。
肺疾患が慢性気管支炎、急性喘息、のう胞性線維症(CF)、慢性閉塞性肺疾患(COPD)または気管支拡張である、請求項16または17に記載の医薬組成物。
請求項1から14のいずれか一項に記載の組成物を治療有効量含む、肺疾患を治療するための医薬。
1つまたは複数のグリコサミノグリカンを噴霧乾燥することを含む、請求項1から14のいずれか一項に記載の組成物中で使用するための粒子を生成する方法。
噴霧乾燥が、制御された速度で動く小滴を生成するための手段を含む噴霧乾燥機の使用を含む、請求項20に記載の方法。
小滴の生成地点から5mmにおける小滴の速度が20m/s未満である、請求項21に記載の方法。
噴霧乾燥機が超音波ネブライザーを含む、請求項21または22に記載の方法。
1つまたは複数のグリコサミノグリカンを疎水性アミノ酸と同時に噴霧乾燥する、請求項20から23のいずれか一項に記載の方法。
請求項1から14のいずれか一項に記載の組成物中で使用するための粒子を生成する方法であって、空気または圧縮ガスまたは流体の存在下で1つまたは複数のグリコサミノグリカンの粒子をジェットミリングすることを含む方法。
疎水性アミノ酸の存在下で粒子をジェットミリングする、請求項25に記載の方法。
0.1バールと3バールの間の入口圧力でジェットミリングを行う、請求項25または26に記載の方法。
3バールと12バールの間の入口圧力でジェットミリングを行う、請求項25から27のいずれか一項に記載の方法。
少なくとも90体積%の活性粒子がジェットミリングの前に直径20μm未満である、請求項25から28のいずれか一項に記載の方法。
生成する乾燥粒子の90%がレーザー回折によって測定して10μm未満の大きさを有する、請求項20から29のいずれか一項に記載の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0321611.6 | 2003-09-15 | ||
| GBGB0321611.6A GB0321611D0 (en) | 2003-09-15 | 2003-09-15 | Pharmaceutical compositions |
| GBGB0327723.3A GB0327723D0 (en) | 2003-09-15 | 2003-11-28 | Pharmaceutical compositions |
| GB0327723.3 | 2003-11-28 | ||
| PCT/GB2004/003932 WO2005025540A2 (en) | 2003-09-15 | 2004-09-15 | Mucoactive agents for treating a pulmonary disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011243533A Division JP2012031204A (ja) | 2003-09-15 | 2011-11-07 | 肺疾患を治療するための粘液活性剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505830A JP2007505830A (ja) | 2007-03-15 |
| JP2007505830A5 true JP2007505830A5 (ja) | 2011-08-04 |
| JP4913595B2 JP4913595B2 (ja) | 2012-04-11 |
Family
ID=34315438
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525902A Expired - Fee Related JP4913595B2 (ja) | 2003-09-15 | 2004-09-15 | 肺疾患を治療するための粘液活性剤 |
| JP2011243533A Pending JP2012031204A (ja) | 2003-09-15 | 2011-11-07 | 肺疾患を治療するための粘液活性剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011243533A Pending JP2012031204A (ja) | 2003-09-15 | 2011-11-07 | 肺疾患を治療するための粘液活性剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7928089B2 (ja) |
| EP (2) | EP1663151A2 (ja) |
| JP (2) | JP4913595B2 (ja) |
| KR (1) | KR20060082865A (ja) |
| CN (1) | CN1874757B (ja) |
| AU (1) | AU2004271778B2 (ja) |
| BR (1) | BRPI0414425A (ja) |
| CA (1) | CA2538399A1 (ja) |
| GB (1) | GB0327723D0 (ja) |
| IL (1) | IL173987A0 (ja) |
| NO (1) | NO20061254L (ja) |
| NZ (1) | NZ545550A (ja) |
| RU (1) | RU2363448C2 (ja) |
| SG (1) | SG146649A1 (ja) |
| WO (1) | WO2005025540A2 (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| ES2848385T3 (es) * | 2003-11-12 | 2021-08-09 | Univ Pennsylvania | Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana |
| US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| DK1755661T3 (da) * | 2004-05-12 | 2014-06-16 | Brigham & Womens Hospital | Gelsolin til anvendelse til behandling af infektioner |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0525254D0 (en) * | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| HUE035884T2 (en) | 2006-03-15 | 2018-05-28 | Brigham & Womens Hospital Inc | The use of gelsolin for the diagnosis and treatment of inflammatory diseases |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| MX2009003002A (es) * | 2006-09-19 | 2009-06-01 | Discovery Lab Inc | Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. |
| CN101433521B (zh) * | 2007-11-14 | 2012-08-08 | 中国医学科学院药用植物研究所 | 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法 |
| EP2250280B1 (en) | 2008-01-25 | 2014-12-03 | The General Hospital Corporation | Therapeutic uses of gelsolin in renal failure |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| WO2010102065A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
| ES2873502T3 (es) | 2009-03-27 | 2021-11-03 | Bend Res Inc | Proceso de secado por pulverización |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| PT2611530T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Aparelho de secagem por pulverização e métodos de utilização do mesmo |
| US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
| US9248584B2 (en) | 2010-09-24 | 2016-02-02 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| WO2012073025A1 (en) * | 2010-11-30 | 2012-06-07 | Vectura Limited | Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd |
| US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
| EP2812031A4 (en) * | 2012-02-06 | 2015-11-04 | Univ Iowa Res Found | METHOD FOR REGULATING CFTR EXPRESSION AND PROCESSING |
| US9707228B2 (en) * | 2012-05-21 | 2017-07-18 | Agency For Science, Technology And Research | Dry powder formulation |
| ITMI20121052A1 (it) * | 2012-06-18 | 2013-12-19 | Ecupharma Srl | Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio |
| GB201305825D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| US9078853B2 (en) | 2013-06-18 | 2015-07-14 | Cmpd Licensing, Llc | Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders |
| SI3043776T1 (sl) | 2013-09-11 | 2024-03-29 | Eagle Biologics, Inc. | Tekoče proteinske formulacije, ki vsebujejo vodotopna organska barvila |
| HUE049339T2 (hu) | 2014-09-09 | 2020-09-28 | Vectura Ltd | Glikopirrolátot tartalmazó készítmény, eljárás és berendezés |
| EP3200804A4 (en) * | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| SI3204095T1 (sl) * | 2014-10-10 | 2019-08-30 | Ablynx N.V. | Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom |
| JP2017538779A (ja) | 2014-10-10 | 2017-12-28 | アブリンクス・エヌ・フェー | Ｒｓｖ感染の治療方法 |
| EP3212169B1 (en) | 2014-10-31 | 2021-01-13 | Bend Research, Inc. | Process for forming active domains dispersed in a matrix |
| CN105920020B (zh) * | 2016-06-23 | 2019-01-08 | 潘海英 | 一种治疗肺部疾病的药物组合物及其制备方法和用途 |
| GB201611639D0 (en) | 2016-07-04 | 2016-08-17 | Ockham Biotech Ltd | Delivery device and formulation |
| AU2017341815B2 (en) * | 2016-10-14 | 2023-06-15 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
| US11986448B2 (en) | 2016-11-17 | 2024-05-21 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| TR201722950A2 (tr) * | 2017-12-29 | 2019-07-22 | Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi | Koah tedavisinde yeni farmasötik bileşimler. |
| IT201800007928A1 (it) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio |
| CN113645968A (zh) * | 2019-03-18 | 2021-11-12 | 西达赛奈医疗中心 | 治疗胃肠疾病和障碍的组合物和方法 |
| US11298355B2 (en) | 2019-05-16 | 2022-04-12 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| KR102250876B1 (ko) * | 2019-07-18 | 2021-05-11 | 충북대학교 산학협력단 | 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물 |
Family Cites Families (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734401A (en) * | 1986-03-17 | 1988-03-29 | W. R. Grace & Co. | Process for spray drying amino acid compositions |
| GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| DK0630230T3 (da) * | 1992-03-10 | 1997-06-02 | Fisons Plc | Farmaceutiske inhaleringspræparater |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6673335B1 (en) | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| JPH08511764A (ja) * | 1992-07-24 | 1996-12-10 | ケネディ，トーマス・ピー | 好中球エラスターゼ及びカテプシンｇの阻害方法及び阻害薬 |
| US5668118A (en) * | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5296471A (en) * | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| GB9313650D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4425255A1 (de) * | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US5980865A (en) * | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
| US5690910A (en) * | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
| AU709262B2 (en) * | 1995-10-17 | 1999-08-26 | Board Of Regents, The University Of Texas System | Insoluble drug delivery |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| DK0896525T3 (da) * | 1996-04-29 | 2003-12-01 | Quadrant Technologies Ltd | Fremgangsmåder til tørpulverinhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5990097A (en) * | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| JP2001507702A (ja) * | 1996-12-31 | 2001-06-12 | インヘイル・セラピューティックス・システムズ・インコーポレテッド | 親水性賦形剤を有する疎水性薬剤の水性懸濁液を噴霧乾燥させる方法およびその方法によって作製された組成物 |
| US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| GB9703673D0 (en) | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| US20010046974A1 (en) | 1997-06-06 | 2001-11-29 | Hamilton Civic Hospitals Res Dev., Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| WO1998055515A1 (en) * | 1997-06-06 | 1998-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| CA2209342A1 (en) | 1997-06-30 | 1998-12-30 | The University Of British Columbia | Use of dextran and other oligomeric saccharides to improve airway clearance |
| IT1296998B1 (it) | 1997-12-19 | 1999-08-03 | Derivati Organici Lab | Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d |
| US20030118514A1 (en) | 1998-03-26 | 2003-06-26 | Glaxo Wellcome Inc. | Compositions for inhalation |
| US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| US6926911B1 (en) * | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| DE60026982T2 (de) | 1999-04-05 | 2006-11-16 | Mannkind Corp., Danbury | Verfahren zur bildung von feinem pulver |
| WO2000061178A1 (en) * | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US6560897B2 (en) * | 1999-05-03 | 2003-05-13 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
| HUP0201712A3 (en) | 1999-06-30 | 2003-03-28 | Weitz Jeffrey I Ancaster | Clot associated coagulation factors inhibiting heparin compositions |
| ITMI991582A1 (it) * | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| ES2161615B1 (es) * | 1999-07-23 | 2003-03-16 | Rovi Lab Farmaceut Sa | Composiciones de heparinas de muy bajo peso molecular. |
| US20020081266A1 (en) | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
| CA2382259A1 (en) * | 1999-08-26 | 2001-03-08 | Governors Of The University Of Alberta | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| ES2343124T3 (es) * | 1999-10-29 | 2010-07-23 | Novartis Ag | Composiciones de polvo seco con dispersabilidad mejorada. |
| DE19953317C1 (de) * | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| EP1129705A1 (en) * | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| CA2340836A1 (en) | 2000-03-18 | 2001-09-18 | Degussa Ag | Granular product |
| US6369115B1 (en) * | 2000-03-20 | 2002-04-09 | Dura Pharmaceuticals, Inc. | Stabilized powder formulations |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| US20050032745A1 (en) | 2000-05-04 | 2005-02-10 | Hamilton Civic Hospitals Res Dev., Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| CN1197587C (zh) | 2000-06-09 | 2005-04-20 | 中国科学院上海细胞生物学研究所 | N－位脱硫酸肝素在预防和治疗炎症中的应用 |
| US7744855B2 (en) * | 2000-06-27 | 2010-06-29 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US7575761B2 (en) * | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
| US6969705B2 (en) * | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| UA75375C2 (en) * | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| JP2004523479A (ja) | 2000-10-18 | 2004-08-05 | マサチューセッツ インスティテュート オブ テクノロジー | 多糖の肺送達に関する方法および産物 |
| DE60137452D1 (de) | 2000-11-29 | 2009-03-05 | Itoham Foods Inc | Pulverzubereitungen und verfahren zu ihrer herstellung |
| PT1920763E (pt) | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
| EP1337240B2 (en) | 2000-11-30 | 2014-09-24 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| ES2334642T5 (es) | 2000-11-30 | 2016-03-07 | Vectura Limited | Partículas para usar en una composición farmacéutica |
| GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
| BR0115524A (pt) * | 2000-12-22 | 2003-09-16 | Aspen Aerogels Inc | Pó seco dispersìvel para transferência pulmonar e método de tratamento de um estado de doença responsivo ao tratamento por meio de um agente terapêutico |
| GB0102902D0 (en) | 2001-02-06 | 2001-03-21 | Innovata Biomed Ltd | Medicaments |
| GB0106403D0 (en) | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| DE10141376A1 (de) * | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Inhalationspulvern |
| DE10141377A1 (de) * | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Aufstreuverfahren zur Herstellung von Pulverformulierungen |
| JP2005507881A (ja) | 2001-09-17 | 2005-03-24 | グラクソ グループ リミテッド | 乾燥粉末医薬製剤 |
| US20030091513A1 (en) | 2001-10-03 | 2003-05-15 | Mohsen Nahed M. | Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media |
| ITMI20012174A1 (it) | 2001-10-18 | 2003-04-18 | Univ Parma | Polvere per somministrazione nasale di farmaci |
| US20050123509A1 (en) | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| WO2003035051A2 (en) * | 2001-10-19 | 2003-05-01 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
| KR100951750B1 (ko) | 2001-11-01 | 2010-04-09 | 노바르티스 아게 | 분무 건조 방법 및 그 조성물 |
| CN1607941A (zh) | 2001-11-19 | 2005-04-20 | 贝克顿迪肯森公司 | 粒状药物组合物 |
| EP1458361A4 (en) | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
| US20060188451A1 (en) | 2001-12-21 | 2006-08-24 | Aspen Aerogels, Inc. | Aerogel based pharmaceutical formulations |
| US20030124087A1 (en) | 2001-12-26 | 2003-07-03 | Amitie Co. Ltd. | Anti-adhesion barrier |
| ES2565028T3 (es) * | 2002-02-18 | 2016-03-30 | Ockham Biotech Limited | Terapia de combinación para trastornos respiratorios |
| CA2516318C (en) * | 2002-02-18 | 2011-07-19 | University Of Southampton | Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd |
| EP1549337B1 (en) * | 2002-02-18 | 2014-08-13 | Ockham Biotech Limited | Combination of DNase I and glycosaminoglycans for use in extracellular DNA clearance |
| US20030232019A1 (en) * | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| FI116657B (fi) | 2002-03-28 | 2006-01-31 | Focus Inhalation Oy | Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö |
| US20050201948A1 (en) | 2002-04-12 | 2005-09-15 | Ellison Mark Jason H | Excipient for use in dry powder inhalation preparations |
| CA2483917C (en) | 2002-05-02 | 2013-07-30 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| US20050220720A1 (en) | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
| US20040028746A1 (en) | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| GB0219511D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
| US20040043064A1 (en) | 2002-08-29 | 2004-03-04 | Iorio Theodore L. | Dosage forms having reduced moisture transmission |
| WO2004030659A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| GB0226274D0 (en) * | 2002-11-11 | 2002-12-18 | Medpharm Ltd | Metered dose inhalation preparations |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| GB0300427D0 (en) | 2003-01-09 | 2003-02-05 | Univ Strathclyde | Pharmaceutical composition |
| GB0304540D0 (en) | 2003-02-27 | 2003-04-02 | Elan Drug Delivery Ltd | Particle formulation and its preparation |
| US6933372B2 (en) * | 2003-03-07 | 2005-08-23 | Warner-Lambert Company | Method to produce a solid form of heparin |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| CA2435632A1 (en) | 2003-07-21 | 2005-01-21 | Warren Hugh Finlay | Formulation of powder containing nanoparticles for aerosol delivery to the lung |
| AU2004258971A1 (en) | 2003-07-22 | 2005-02-03 | Baxter Healthcare S.A. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| US9345664B2 (en) | 2003-09-02 | 2016-05-24 | Norton Healthcare Ltd | Process for preparing a medicament |
| US20060292081A1 (en) * | 2003-09-15 | 2006-12-28 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| WO2005032483A2 (en) * | 2003-10-01 | 2005-04-14 | Momenta Pharmaceuticals, Inc. | Polysaccharides for pulmonary delivery of active agents |
| CA2541445A1 (en) * | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Nanoparticles for drug delivery |
| CN1261105C (zh) | 2003-12-05 | 2006-06-28 | 吉林省辽源亚东药业股份有限公司 | 一种复方吡拉西坦脑蛋白水解物制剂及制备方法 |
| GB0329208D0 (en) | 2003-12-17 | 2004-01-21 | Ici Plc | Particulate materials |
| US7776241B2 (en) | 2003-12-23 | 2010-08-17 | Niro A/S | Method and apparatus for producing micro particles |
| US7928059B2 (en) * | 2004-02-24 | 2011-04-19 | Wisconsin Alumni Research Foundation | Use of neuropeptides for traumatic cartilage injury |
| SE528121C2 (sv) | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
| PT1748781E (pt) * | 2004-05-27 | 2013-01-22 | Baxter Int | Processos para o tratamento de distúrbios de hemorragias utilizando polissacarídeos sulfatados |
| US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| EP1768678A4 (en) | 2004-06-30 | 2009-09-23 | Paul L Deangelis | METHODS FOR SELECTIVE TREATMENT OF DISEASES BY SPECIFIC GLYCOSAMINOGLYCAN POLYMERS |
| US20060014698A1 (en) * | 2004-07-14 | 2006-01-19 | O'connor Michael F | Nebulized pharmaceutical compositions for the treatment of bronchial disorders |
| EP1781257B1 (en) | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| WO2006026502A1 (en) | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| WO2006085101A2 (en) | 2005-02-10 | 2006-08-17 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US20090186088A1 (en) | 2005-03-18 | 2009-07-23 | Nanomaterials Technology Pte Ltd | Inhalable drug |
| JP5483874B2 (ja) | 2005-05-05 | 2014-05-07 | サノフィ−アベンティス・ユー・エス・エルエルシー | 安定なナノ粒子処方物 |
| ES2616295T3 (es) | 2005-10-12 | 2017-06-12 | Seikagaku Corporation | Agente para aplicar a mucosa y procedimiento para la producción del mismo |
| US20070098803A1 (en) | 2005-10-27 | 2007-05-03 | Primet Precision Materials, Inc. | Small particle compositions and associated methods |
| US7597094B2 (en) * | 2005-11-29 | 2009-10-06 | Leon Monroe Pittman | Compound bow maintenance press and method for compressing a compound bow from the bow limb ends |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| US20080050444A1 (en) | 2005-12-16 | 2008-02-28 | Rajneesh Taneja | Pharmaceutical compositions of ilaparazole |
| DE102005062270A1 (de) | 2005-12-24 | 2007-06-28 | Bayer Technology Services Gmbh | Geschmacksmaskierung von Pulvern |
| US20070166386A1 (en) | 2006-01-13 | 2007-07-19 | Chinea Vanessa I | Nanoparticle formation of pharmaceutical ingredients |
| TW200817047A (en) | 2006-04-03 | 2008-04-16 | Teva Pharma | Drug microparticles |
| US8257685B2 (en) | 2006-04-04 | 2012-09-04 | Stc.Unm | Swellable particles for drug delivery |
| US20080299210A1 (en) | 2006-04-13 | 2008-12-04 | Min Wei | Stable nanosized amorphous drug |
| WO2008002485A2 (en) | 2006-06-23 | 2008-01-03 | Alza Corporation | Increased amorphous stability of poorly water soluble drugs by nanosizing |
| WO2008011051A1 (en) | 2006-07-17 | 2008-01-24 | Liquidia Technologies, Inc. | Nanoparticle fabrication methods, systems, and materials |
| GB0617171D0 (en) | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
| EP1944018A1 (en) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| US20090203789A1 (en) * | 2008-01-31 | 2009-08-13 | Multi Formulations Ltd. | Fast Dissolution Amino Acid Composition |
-
2003
- 2003-11-28 GB GBGB0327723.3A patent/GB0327723D0/en not_active Ceased
-
2004
- 2004-09-15 BR BRPI0414425-2A patent/BRPI0414425A/pt not_active IP Right Cessation
- 2004-09-15 US US10/571,184 patent/US7928089B2/en not_active Expired - Fee Related
- 2004-09-15 JP JP2006525902A patent/JP4913595B2/ja not_active Expired - Fee Related
- 2004-09-15 SG SG200806902-3A patent/SG146649A1/en unknown
- 2004-09-15 RU RU2006112583/15A patent/RU2363448C2/ru not_active IP Right Cessation
- 2004-09-15 WO PCT/GB2004/003932 patent/WO2005025540A2/en active Application Filing
- 2004-09-15 CA CA002538399A patent/CA2538399A1/en not_active Abandoned
- 2004-09-15 EP EP04768478A patent/EP1663151A2/en not_active Ceased
- 2004-09-15 NZ NZ545550A patent/NZ545550A/en not_active IP Right Cessation
- 2004-09-15 EP EP20100179071 patent/EP2277505A3/en not_active Ceased
- 2004-09-15 KR KR1020067005166A patent/KR20060082865A/ko active IP Right Grant
- 2004-09-15 CN CN2004800326797A patent/CN1874757B/zh not_active Expired - Fee Related
- 2004-09-15 AU AU2004271778A patent/AU2004271778B2/en not_active Ceased
-
2006
- 2006-02-27 IL IL173987A patent/IL173987A0/en unknown
- 2006-03-17 NO NO20061254A patent/NO20061254L/no not_active Application Discontinuation
-
2011
- 2011-03-08 US US13/043,117 patent/US20110217339A1/en not_active Abandoned
- 2011-11-07 JP JP2011243533A patent/JP2012031204A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505830A5 (ja) | ||
| RU2006112583A (ru) | Фармацевтические композиции | |
| JP6141906B2 (ja) | スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤 | |
| JP5739197B2 (ja) | 多孔性微粒子および使用方法 | |
| Odziomek et al. | Conception, preparation and properties of functional carrier particles for pulmonary drug delivery | |
| ITMI990455A1 (it) | Particelle veicolo modificate da utilizzarsi nella preparazione di formulazioni farmaceutiche sotto forma di polimeri per inalazione e loro | |
| WO2007123793A3 (en) | Swellable particles for drug delivery | |
| Yang et al. | Dry powder inhaler formulation of lipid–polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles | |
| CN103536583B (zh) | 一种原花青素缓释纳米微球及制备方法和应用 | |
| Kramek-Romanowska et al. | Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation | |
| CN108135851A (zh) | 射流研磨方法 | |
| Tse et al. | Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology | |
| JP2019517541A5 (ja) | ||
| WO2012061902A1 (en) | Micronised spray-dried particles comprising polymyxin | |
| Behara et al. | Development of high efficiency ventilation bag actuated dry powder inhalers | |
| Lee et al. | Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy | |
| CN105012278B (zh) | 一种干粉吸入粉雾剂载体蔗糖及其制备方法 | |
| Albetawi | Current Research on Spray-Dried Chitosan Nanocomposite Microparticles for Pulmonary Drug Delivery | |
| AU2013201437B2 (en) | DPI formulation containing sulfoalkyl ether cyclodextrin | |
| JP3888753B2 (ja) | 持続性粉末状吸入用医薬品組成物 | |
| JP2023528883A (ja) | 呼吸器系傷害改善用医薬組成物及び呼吸器系傷害改善用医薬組成物の製造のための用途 | |
| Fernandes et al. | Impact of Spray Drying on Superoxide Dismutase Activity in Composite Systems with Optimal Aerodynamic Performance for Dry Powder Inhalers | |
| KABRA et al. | Comparison between spray drying and freeze drying techniques for the preparation of microparticles for delivery via a dry powder inhaler to treat cystic fibrosis. | |
| Xu et al. | A novel pullulan excipient for inhalable spray-dried powders | |
| EP2340816A1 (en) | A plant for manufacturing composite carrier particles |